揭示2型糖尿病骨折风险:纵向糖化血红蛋白水平与药物的关联
这项基于美国OptumLabs数据库的回顾性人群队列研究纳入157439例55岁以上、平均HbA1c≥6%的2型糖尿病患者,在2年HbA1c观察期和2年骨折随访期内分析。校正协变量后,血糖控制不佳与全骨折风险增加29%相关(HR 1.29;95%CI 1.22-1.36);二甲双胍和DPP4抑制剂与全骨折风险降低相关,胰岛素、噻唑烷二酮类和格列奈类与风险增加相关。
要点
- 血糖控制不佳的2型糖尿病患者全骨折风险较血糖控制达标者增加29%(HR 1.29;95%CI 1.22-1.36)。
- 二甲双胍(HR 0.88)和DPP4抑制剂(HR 0.93)与全骨折风险降低相关。
- 胰岛素(HR 1.26)、噻唑烷二酮类(HR 1.23)和格列奈类(HR 1.12)与全骨折风险增加相关。
核心结论
- 纵向2年HbA1c与2型糖尿病患者2年随访期间全骨折风险升高独立相关。
- 二甲双胍和DPP4抑制剂可用于管理2型糖尿病骨折风险。
研究设计与样本
- 回顾性人群队列研究,使用OptumLabs Data Warehouse去标识化理赔与电子健康记录数据,时间范围为2007年1月1日至2015年9月30日。
- 从4018250名美国Medicare Advantage/Commercial参保的2型糖尿病诊断者中选取157439例年龄≥55岁、平均HbA1c值≥6%的2型糖尿病患者。
- 每名个体在2年HbA1c观察期和2年骨折随访期内进行研究,测量所有骨折和脆性骨折。
主要发现
- 校正协变量后,血糖控制不佳的2型糖尿病患者全骨折风险较血糖控制达标者增加29%(HR 1.29;95%CI 1.22-1.36)。
- 二甲双胍治疗与全骨折风险降低相关(HR 0.88;95%CI 0.85-0.92),DPP4抑制剂治疗与全骨折风险降低相关(HR 0.93;95%CI 0.88-0.98)。
- 胰岛素治疗与全骨折风险增加相关(HR 1.26;95%CI 1.21-1.32),噻唑烷二酮类治疗与全骨折风险增加相关(HR 1.23;95%CI 1.18-1.29),格列奈类治疗与全骨折风险增加相关(HR 1.12;95%CI 1.00-1.26),所有P值<0.05。
- 双膦酸盐在2型糖尿病组和非糖尿病组中与骨折风险增加的关联相似。
关键数值与推荐
- 血糖控制不佳的2型糖尿病患者全骨折风险HR 1.29(95%CI 1.22-1.36),对照为血糖控制达标的2型糖尿病患者。
- 二甲双胍全骨折风险HR 0.88(95%CI 0.85-0.92);DPP4抑制剂HR 0.93(95%CI 0.88-0.98)。
- 胰岛素全骨折风险HR 1.26(95%CI 1.21-1.32);噻唑烷二酮类HR 1.23(95%CI 1.18-1.29);格列奈类HR 1.12(95%CI 1.00-1.26)。
临床怎么用
- 作者结论指出,二甲双胍和DPP4抑制剂可用于管理2型糖尿病骨折风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Fracture risk is underestimated in people with type 2 diabetes (T2D). OBJECTIVE: To investigate the longitudinal relationship of glycated hemoglobin (HbA1c) and common medications on fracture risk in people with T2D. METHODS: This retrospective population-based cohort study was conducted using de-identified claims and electronic health record data obtained from the OptumLabs Data Warehouse for the period January 1, 2007, to September 30, 2015. For each individual, the study was conducted within a 2-year HbA1c observation period and a 2-year fracture follow-up period. A cohort of 157 439 individuals with T2D [age ≥ 55 years with mean HbA1c value ≥ 6%] were selected from 4 018 250 US Medicare Advantage/Commercial enrollees with a T2D diagnosis. All fractures and fragility fractures were measured. RESULTS: With covariates adjusted, poor glycemic control in T2D individuals was associated with an 29% increase of all fracture risk, compared with T2D individuals who had adequate glycemic control (HR: 1.29; 95% CI, 1.22-1.36). Treatment with metformin (HR: 0.88; 95% CI, 0.85-0.92) and DPP4 inhibitors (HR: 0.93; 95% CI, 0.88-0.98) was associated with a reduced all fracture risk, while insulin (HR: 1.26; 95% CI, 1.21-1.32), thiazolidinediones (HR: 1.23; 95% CI, 1.18-1.29), and meglitinides (HR: 1.12; 95% CI, 1.00-1.26) were associated with an increased all fracture risk (All P value < 0.05). Bisphosphonates were associated similarly with increased fracture risk in the T2D and nondiabetic groups. CONCLUSION: Longitudinal 2-year HbA1c is independently associated with elevated all fracture risk in T2D individuals during a 2-year follow-up period. Metformin and DPP4 inhibitors can be used for management of T2D fracture risk.
引用
- Wang B, Wang Z, Poundarik AA, et al. Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications. J Clin Endocrinol Metab. 2022. PMID: 34888676. doi:10.1210/clinem/dgab882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。